Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
1740 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Non-Hodgkin Lymphoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape. Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively. Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 11 Non-Hodgkin Lymphoma - Overview 12 Non-Hodgkin Lymphoma - Therapeutics Development 13 Non-Hodgkin Lymphoma - Therapeutics Assessment 85 Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 111 Non-Hodgkin Lymphoma - Drug Profiles 233 Non-Hodgkin Lymphoma - Dormant Projects 1656 Non-Hodgkin Lymphoma - Discontinued Products 1676 Non-Hodgkin Lymphoma - Product Development Milestones 1684 Appendix 1692
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017 60 Number of Products under Development by Companies, H1 2017 62 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 63 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 64 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 65 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 66 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 67 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 68 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 69 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 70 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 71 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 72 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 73 Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 74 Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 75 Number of Products under Development by Universities/Institutes, H1 2017 76 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 77 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 78 Products under Development by Companies, H1 2017 79 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 80 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 81 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 82 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 83 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 84 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 85 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 86 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 87 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 88 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 89 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 90 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 91 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 92 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 93 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 94 Products under Development by Companies, H1 2017 (Contd..16), H1 2017 95 Products under Development by Companies, H1 2017 (Contd..17), H1 2017 96 Products under Development by Companies, H1 2017 (Contd..18), H1 2017 97 Products under Development by Companies, H1 2017 (Contd..19), H1 2017 98 Products under Development by Companies, H1 2017 (Contd..20), H1 2017 99 Products under Development by Companies, H1 2017 (Contd..21), H1 2017 100 Products under Development by Companies, H1 2017 (Contd..22), H1 2017 101 Products under Development by Companies, H1 2017 (Contd..23), H1 2017 102 Products under Development by Companies, H1 2017 (Contd..24), H1 2017 103 Products under Development by Companies, H1 2017 (Contd..25), H1 2017 104 Products under Development by Companies, H1 2017 (Contd..26), H1 2017 105 Products under Development by Companies, H1 2017 (Contd..27), H1 2017 106 Products under Development by Companies, H1 2017 (Contd..28), H1 2017 107 Products under Development by Companies, H1 2017 (Contd..29), H1 2017 108 Products under Development by Companies, H1 2017 (Contd..30), H1 2017 109 Products under Development by Companies, H1 2017 (Contd..31), H1 2017 110 Products under Development by Companies, H1 2017 (Contd..32), H1 2017 111 Products under Development by Companies, H1 2017 (Contd..33), H1 2017 112 Products under Development by Companies, H1 2017 (Contd..34), H1 2017 113 Products under Development by Companies, H1 2017 (Contd..35), H1 2017 114 Products under Development by Companies, H1 2017 (Contd..36), H1 2017 115 Products under Development by Companies, H1 2017 (Contd..37), H1 2017 116 Products under Development by Companies, H1 2017 (Contd..38), H1 2017 117 Products under Development by Companies, H1 2017 (Contd..39), H1 2017 118 Products under Development by Companies, H1 2017 (Contd..40), H1 2017 119 Products under Development by Companies, H1 2017 (Contd..41), H1 2017 120 Products under Development by Companies, H1 2017 (Contd..42), H1 2017 121 Products under Development by Companies, H1 2017 (Contd..43), H1 2017 122 Products under Development by Companies, H1 2017 (Contd..44), H1 2017 123 Products under Development by Companies, H1 2017 (Contd..45), H1 2017 124 Products under Development by Companies, H1 2017 (Contd..46), H1 2017 125 Products under Development by Companies, H1 2017 (Contd..47), H1 2017 126 Products under Development by Universities/Institutes, H1 2017 127 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 128 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 129 Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 131 Number of Products by Stage and Target, H1 2017 133 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 134 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 135 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 136 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 137 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 138 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 139 Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 140 Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 141 Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017 142 Number of Products by Stage and Mechanism of Action, H1 2017 144 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 145 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 146 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 147 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 148 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 149 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 150 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 151 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 152 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017 153 Number of Products by Stage and Route of Administration, H1 2017 155 Number of Products by Stage and Molecule Type, H1 2017 157 Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2017 158 Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2017 158 Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2017 159 Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2017 160 Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2017 162 Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2017 162 Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2017 163 Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2017 164 Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2017 164 Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2017 165 Non-Hodgkin Lymphoma - Pipeline by Alfa Wassermann SpA, H1 2017 165 Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2017 166 Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2017 166 Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2017 167 Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2017 168 Non-Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc, H1 2017 168 Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2017 169 Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H1 2017 169 Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2017 170 Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 170 Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2017 171 Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H1 2017 171 Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2017 172 Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2017 172 Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017 173 Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2017 173 Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H1 2017 174 Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 174 Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2017 175 Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2017 177 Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 177 Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2017 178 Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H1 2017 178 Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2017 179 Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2017 179 Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2017 180 Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2017 180 Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H1 2017 181 Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2017 181 Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017 182 Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 182 Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2017 183 Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 183 Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H1 2017 184 Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2017 184 Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H1 2017 185 Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2017 186 Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2017 188 Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2017 188 Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2017 189 Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2017 189 Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2017 190 Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2017 191 Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2017 191 Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2017 192 Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2017 193 Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H1 2017 194 Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2017 194 Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2017 195 Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017 195 Non-Hodgkin Lymphoma - Pipeline by Cleave Biosciences Inc, H1 2017 196 Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2017 196 Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H1 2017 197 Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 197 Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017 198 Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017 198 Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H1 2017 199 Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H1 2017 200 Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 201 Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H1 2017 201 Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 202 Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H1 2017 202 Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H1 2017 203 Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H1 2017 203 Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017 204 Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H1 2017 204 Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2017 205 Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H1 2017 206 Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2017 207 Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H1 2017 207 Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 208 Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H1 2017 209 Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H1 2017 209 Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H1 2017 210 Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H1 2017 210 Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H1 2017 211 Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H1 2017 212 Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H1 2017 212 Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H1 2017 213 Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2017 214 Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H1 2017 214 Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H1 2017 215 Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H1 2017 215 Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H1 2017 216 Non-Hodgkin Lymphoma - Pipeline by Hutchison China MediTech Ltd, H1 2017 216 Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2017 217 Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H1 2017 217 Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H1 2017 218 Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H1 2017 218 Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H1 2017 219 Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H1 2017 219 Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H1 2017 220 Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H1 2017 221 Non-Hodgkin Lymphoma - Pipeline by Immunwork Inc, H1 2017 221 Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H1 2017 222 Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H1 2017 223 Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H1 2017 223 Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H1 2017 224 Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H1 2017 224 Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H1 2017 225 Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2017 225 Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H1 2017 226 Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H1 2017 227 Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H1 2017 227 Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 228 Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H1 2017 229 Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H1 2017 230 Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H1 2017 230 Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 231 Non-Hodgkin Lymphoma - Pipeline by LFB SA, H1 2017 231 Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2017 232 Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H1 2017 233 Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H1 2017 233 Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H1 2017 234 Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H1 2017 234 Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H1 2017 235 Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H1 2017 236 Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2017 237 Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H1 2017 238 Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 239 Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H1 2017 240 Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H1 2017 240 Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H1 2017 241 Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H1 2017 241 Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H1 2017 242 Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2017 242 Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H1 2017 243 Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H1 2017 243 Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H1 2017 244 Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2017 244 Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017 245 Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2017 246 Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2017 246 Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H1 2017 247 Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H1 2017 247 Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H1 2017 248 Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H1 2017 248 Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H1 2017 249 Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 249 Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 250 Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2017 251 Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2017 251 Non-Hodgkin Lymphoma - Pipeline by OXIS International Inc, H1 2017 253 Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H1 2017 253 Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H1 2017 254 Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H1 2017 254 Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H1 2017 255 Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H1 2017 255 Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 255 Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H1 2017 256 Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H1 2017 256 Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 257 Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2017 257 Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 258 Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H1 2017 258 Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2017 259 Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2017 259 Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2017 260 Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H1 2017 261 Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H1 2017 262 Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H1 2017 262 Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017 263 Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017 263 Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H1 2017 264 Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H1 2017 264 Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2017 265 Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H1 2017 265 Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H1 2017 266 Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H1 2017 266 Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017 267 Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H1 2017 268 Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017 269 Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H1 2017 269 Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H1 2017 270 Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H1 2017 270 Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 270 Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017 271 Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H1 2017 271 Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H1 2017 272 Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 272 Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H1 2017 273 Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2017 273 Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 274 Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H1 2017 274 Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H1 2017 275 Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H1 2017 275 Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H1 2017 276 Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H1 2017 276 Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H1 2017 277 Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2017 277 Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H1 2017 278 Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H1 2017 278 Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H1 2017 279 Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H1 2017 279 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 1703 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..1), H1 2017 1704 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..2), H1 2017 1705 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..3), H1 2017 1706 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..4), H1 2017 1707 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..5), H1 2017 1708 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..6), H1 2017 1710 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..7), H1 2017 1711 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..8), H1 2017 1712 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..9), H1 2017 1713 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..10), H1 2017 1714 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..11), H1 2017 1715 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..12), H1 2017 1716 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..13), H1 2017 1717 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..14), H1 2017 1718 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..15), H1 2017 1719 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..16), H1 2017 1720 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..17), H1 2017 1721 Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..18), H1 2017 1722 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 1723 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..1), H1 2017 1724 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..2), H1 2017 1725 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..3), H1 2017 1726 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..4), H1 2017 1727 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..5), H1 2017 1728 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..6), H1 2017 1729 Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..7), H1 2017 1730
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
